FI4313058T3 - Roginolisibia käsittävä koostumus ja annosteluohjelma syövän tai tulehdus- tai autoimmunisairauden hoitoon - Google Patents

Roginolisibia käsittävä koostumus ja annosteluohjelma syövän tai tulehdus- tai autoimmunisairauden hoitoon Download PDF

Info

Publication number
FI4313058T3
FI4313058T3 FIEP22719266.3T FI22719266T FI4313058T3 FI 4313058 T3 FI4313058 T3 FI 4313058T3 FI 22719266 T FI22719266 T FI 22719266T FI 4313058 T3 FI4313058 T3 FI 4313058T3
Authority
FI
Finland
Prior art keywords
salt
cancer
compound
formula
disease
Prior art date
Application number
FIEP22719266.3T
Other languages
English (en)
Finnish (fi)
Inventor
Catherine Pickering
Der Veen Lars Van
Michael Lahn
Rebeca Zorrilla
Zoë Johnson
Original Assignee
Ionctura Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104416.9A external-priority patent/GB202104416D0/en
Priority claimed from GBGB2117511.2A external-priority patent/GB202117511D0/en
Application filed by Ionctura Sa filed Critical Ionctura Sa
Application granted granted Critical
Publication of FI4313058T3 publication Critical patent/FI4313058T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
FIEP22719266.3T 2021-03-29 2022-03-29 Roginolisibia käsittävä koostumus ja annosteluohjelma syövän tai tulehdus- tai autoimmunisairauden hoitoon FI4313058T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2104416.9A GB202104416D0 (en) 2021-03-29 2021-03-29 Treatment reginmens
GBGB2117511.2A GB202117511D0 (en) 2021-12-03 2021-12-03 Treatment regimens
PCT/EP2022/058283 WO2022207646A1 (en) 2021-03-29 2022-03-29 A pi3k-delta inhibitor for use in treatment regimens

Publications (1)

Publication Number Publication Date
FI4313058T3 true FI4313058T3 (fi) 2025-04-30

Family

ID=81388915

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP22719266.3T FI4313058T3 (fi) 2021-03-29 2022-03-29 Roginolisibia käsittävä koostumus ja annosteluohjelma syövän tai tulehdus- tai autoimmunisairauden hoitoon

Country Status (17)

Country Link
US (2) US12605389B2 (cg-RX-API-DMAC7.html)
EP (2) EP4313058B1 (cg-RX-API-DMAC7.html)
JP (1) JP7839803B2 (cg-RX-API-DMAC7.html)
AU (1) AU2022251843B2 (cg-RX-API-DMAC7.html)
CA (1) CA3212731A1 (cg-RX-API-DMAC7.html)
DK (1) DK4313058T3 (cg-RX-API-DMAC7.html)
ES (1) ES3031295T3 (cg-RX-API-DMAC7.html)
FI (1) FI4313058T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250516T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071610T2 (cg-RX-API-DMAC7.html)
LT (1) LT4313058T (cg-RX-API-DMAC7.html)
MX (1) MX2023011442A (cg-RX-API-DMAC7.html)
PL (1) PL4313058T3 (cg-RX-API-DMAC7.html)
PT (1) PT4313058T (cg-RX-API-DMAC7.html)
RS (1) RS66754B1 (cg-RX-API-DMAC7.html)
SI (1) SI4313058T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022207646A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024184266A1 (en) * 2023-03-03 2024-09-12 Ionctura Sa Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy
JP2026510567A (ja) * 2023-03-03 2026-04-08 アイオンクチュラ・ソシエテ・アノニム 血液悪性腫瘍の治療におけるロギノリシブ及びbcl-2阻害剤の組み合わせ
GB202418087D0 (en) 2024-12-10 2025-01-22 Ionctura Sa Biomarkers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012005518A (es) 2009-11-13 2012-06-19 Merck Serono Sa Derivados de pirazol amina triciclica.
WO2014121901A1 (en) * 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms
US9986723B2 (en) 2014-10-22 2018-06-05 The Board Of Regents Of The University Of Texas System Screen and use of therapeutics for pancreatic ductal adenocarcinoma
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma

Also Published As

Publication number Publication date
CA3212731A1 (en) 2022-10-06
US20260224587A1 (en) 2026-08-06
PT4313058T (pt) 2025-06-02
LT4313058T (lt) 2025-05-26
RS66754B1 (sr) 2025-05-30
AU2022251843B2 (en) 2026-04-09
HRP20250516T1 (hr) 2025-06-20
SI4313058T1 (sl) 2025-07-31
DK4313058T3 (da) 2025-05-12
EP4744651A2 (en) 2026-05-20
ES3031295T3 (en) 2025-07-07
US20240058351A1 (en) 2024-02-22
HUE071610T2 (hu) 2025-09-28
PL4313058T3 (pl) 2025-06-23
MX2023011442A (es) 2023-10-18
JP2024518685A (ja) 2024-05-02
AU2022251843A1 (en) 2023-10-05
EP4313058B1 (en) 2025-03-05
WO2022207646A1 (en) 2022-10-06
JP7839803B2 (ja) 2026-04-02
EP4313058A1 (en) 2024-02-07
US12605389B2 (en) 2026-04-21

Similar Documents

Publication Publication Date Title
ES2774430T3 (es) Novedoso compuesto de 1,2,4-triazina disustituida
ES2853375T3 (es) Sales novedosas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios
US9403802B2 (en) Heterocyclic compound and use therefor
CN116406357A (zh) Mas相关g蛋白受体x2的调节剂及相关产物和方法
CN119219661A (zh) 一种5元杂芳基衍生物及其在医药上的应用
JP2024518685A5 (cg-RX-API-DMAC7.html)
HRP20250516T1 (hr) Pripravak koji sadrži roginolisib i režim za doziranje u liječenju raka ili upalne ili autoimune bolesti
HRP20110097T1 (hr) Derivati fenilpirazola kao nesteroidni ligandi glukokortikoidnih receptora
US20190263799A1 (en) 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
JP5901634B2 (ja) キナゾリン化合物及びその使用方法
CN103827120A (zh) 6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂*
JP2018531288A5 (cg-RX-API-DMAC7.html)
KR20120120252A (ko) 폴로-유사 키나제의 억제제로서의 프테리디논
US12269813B2 (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate
US20190388421A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
US20170197939A1 (en) Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
KR101905295B1 (ko) 나프티리딘디온 유도체
US11560372B2 (en) Heterocyclic compounds useful as modulators of acetylcholine receptors
CN108349974A (zh) 一种取代的吡啶酰胺类化合物及其应用
US20050038104A1 (en) Substitute benzothiophene compounds
WO2018185701A1 (en) Trpv4 antagonists as antitussive agents
WO2025149082A1 (zh) 取代桥环类抑制剂及其制备方法和应用
US10899702B2 (en) HTRPVI chemical agents
JP2022520361A (ja) 複素環式タンパク質キナーゼ阻害剤を含む製剤
KR20260006574A (ko) Kcc2 강화제 및 이의 용도